MediWound Ltd.

NASDAQ:MDWD

Biotechnology

Healthcare
$13.68 -0.60%

-$0.09 today

Market cap
$176.61M
Beta
0.15
P/E (TTM)
-7.0
EPS (TTM)
-$2.03
52W Low $13.54High $21.26

Volume 0.16M

Average 0.09M

MDWD EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

MediWound Ltd.NASDAQ: MDWD

EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026

EPS (Diluted) remains negative

Q1 FY2026 EPS (Diluted) was -$0.23, compared with -$0.07 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.26.

Context

  • EPS (Diluted) grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$1.99 (+5.1%) for the fiscal year ending Dec 2026, a slowdown from the +30.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.23+58.9% QoQ
Last fiscal yearDec 2025
-$2.1+30.7% YoY
LTMMar 2026
-$2.26-8.3% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-242.3%+38.1%+280.3 pp
1 year+30.7%+5.1%-25.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
(2.10) USD
Year-over-year change
+30.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How MDWD compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -8.3% is the 6th highest of 9, against a peer median of +17.4%.
MDWD Competitors
EPS (Diluted) for MDWD and competitors
Company Period LTM YoY 3-year CAGR
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026-$0.2 USD+31.5%—
IVVDInvivyd, Inc.LTM Mar 2026-$0.37 USD+68.8%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$1 USD-29.9%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$1.42 USD+19.8%—
TARAProtara Therapeutics, Inc.LTM Mar 2026-$1.46 USD+15.1%—
IVAInventiva S.A.FY2025-€1.82 EUR+48.6%—
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026-$1.94 USD——
MDWDMediWound Ltd.LTM Mar 2026-$2.26 USD-8.3%—
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026-$3.21 USD-150.8%—
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$5.7 USD-325.7%—
Peer median (excluding MDWD) —+17.4%—

Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue23.76M26.5M18.69M20.22M16.96M
Cost of Revenue14.99M13.33M15.11M17.59M13.71M
Gross Profit8.77M13.17M3.58M2.63M3.25M
Gross Margin36.9%49.7%19.1%13.0%19.2%
Research & Development10.26M10.18M7.47M8.88M14.32M
Selling, General & Admin9.45M10.37M11.38M12.91M13.93M
Operating Expenses19.99M20.83M19.08M22.02M28.53M
Depreciation & Amortization1.24M1.27M1.3M1.48M1.86M
EBITDA(11.38M)(18.25M)(4.8M)(27.93M)(21.47M)
EBITDA Margin-47.9%-68.9%-25.7%-138.1%-126.6%
Operating Income(11.22M)(7.66M)(15.5M)(19.38M)(25.28M)
Operating Margin-47.2%-28.9%-83.0%-95.8%-149.1%
Interest Income11K270K2.34M2.05M1.86M
Interest Expense167K162K335K561K663K
Other Income / Expenses(2.3M)(11.86M)8.97M(10.78M)1.57M
Income Before Tax(13.52M)(19.52M)(6.53M)(30.16M)(23.71M)
Pre-Tax Margin-56.9%-73.7%-35.0%-149.2%-139.8%
Income Tax Expense27K78K185K61K169K
Net Income(13.55M)(19.6M)(6.72M)(30.22M)(23.88M)
Net Margin-57.0%-74.0%-35.9%-149.5%-140.8%
EPS (Basic)(3.48)(3.93)(0.75)(3.03)(2.10)
EPS (Diluted)(3.48)(3.93)(0.75)(3.03)(2.10)
Weighted Avg Shares3.89M4.99M9.01M9.96M11.38M
Weighted Avg Shares (Diluted)3.89M4.99M9.01M9.96M11.38M

MediWound Ltd.

NASDAQ:MDWD

Intrinsic Alpha fair value

Locked

Current Price

$13.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.